macroglobulinemic

English Journal

CD3+ T lymphocytes and interleukin 2 in myelomatous blood hyperviscosity syndrome treated with plasmapheresis.

Usnarska-Zubkiewicz L1.
Archivum immunologiae et therapiae experimentalis.Arch Immunol Ther Exp (Warsz).1998;46(5):317-22.
The study was aimed at testing changes of absolute CD3+ T lymphocyte counts and serum interleukin 2 (IL-2) concentrations in 20 patients suffering from myelomatous and macroglobulinemic hyperviscosity syndrome. Mean values have been calculated from assays made before treatment, immediately after pla
PMID 9832072

Waldenström macroglobulinemia presenting as a renal or perirenal mass: clinical and radiographic features.

Moore DF Jr1, Moulopoulos LA, Dimopoulos MA.
Leukemia & lymphoma.Leuk Lymphoma.1995 Apr;17(3-4):331-4.
Manifestations of macroglobulinemic lymphoma include lymphadenopathy, splenomegaly and bone marrow involvement. Renal presentations are unusual and complications of renal function are even less frequent. A review of all patients diagnosed with Waldenström macroglobulinemia at our institution from J
PMID 8580804

Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.

Dimopoulos MA1, Weber D, Delasalle KB, Keating M, Alexanian R.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.Ann Oncol.1995 Jan;6(1):49-52.
BACKGROUND: Few effective treatments are available for patients with Waldenstrom's macroglobulinemia that is resistant to standard therapies. We assessed the activity of 2-chlorodeoxyadenosine (2CdA) in patients with resistant macroglobulinemia in order to identify those most likely to benefit.PATIE
PMID 7710983

A Macroglobulinemic Case Accompanied by Pulmonary and Cholecystic Lesions Treated with Long-Term Double-Filtration Plasmapheresis : Hematological Disease :

An Effective Therapy by Natural-lnterferon-Alfa in a Chemotherapy-resistant Macroglobulinemic Patient

An Effective Therapy by Natural-lnterferon-Alfa in a Chemotherapy-resistant Macroglobulinemic Patient